T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Rivian
RIVN
|
+$18.7B |
| 2 |
Apple
AAPL
|
+$5.48B |
| 3 |
NVIDIA
NVDA
|
+$5.33B |
| 4 |
Tesla
TSLA
|
+$4.47B |
| 5 |
Microsoft
MSFT
|
+$2.15B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Visa
V
|
+$4.26B |
| 2 |
Meta Platforms (Facebook)
META
|
+$3.3B |
| 3 |
Morgan Stanley
MS
|
+$2.82B |
| 4 |
Global Payments
GPN
|
+$2.43B |
| 5 |
PayPal
PYPL
|
+$2B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 27.36% |
| 2 | Healthcare | 16.09% |
| 3 | Consumer Discretionary | 15.79% |
| 4 | Communication Services | 12.38% |
| 5 | Financials | 10.76% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
76
Broadcom
AVGO
$1.98T
| $3.02B | 0.27% |
45,418,380
+8,468,060
| +23% | +$476M |
|
77
Southern Company
SO
$106B
| $3B | 0.27% |
43,738,622
+8,731,817
| +25% | +$557M |
|
78
S&P Global
SPGI
$121B
| $2.93B | 0.26% |
6,208,936
-681,217
| -10% | -$312M |
|
79
West Pharmaceutical
WST
$24.8B
| $2.93B | 0.26% |
6,241,901
+1,151,427
| +23% | +$496M |
|
80
Marvell Technology
MRVL
$195B
| $2.86B | 0.26% |
32,706,813
-1,413,671
| -4% | -$106M |
|
81
TransUnion
TRU
$15.2B
| $2.83B | 0.25% |
23,842,639
+223,774
| +0.9% | +$25.6M |
|
82
Datadog
DDOG
$86.5B
| $2.75B | 0.25% |
15,435,270
-3,528,775
| -19% | -$599M |
|
83
Medtronic
MDT
$116B
| $2.69B | 0.24% |
25,982,131
+2,284,638
| +10% | +$265M |
|
84
Home Depot
HD
$342B
| $2.67B | 0.24% |
6,425,008
-25,967
| -0.4% | -$9.89M |
|
85
Textron
TXT
$15.3B
| $2.65B | 0.24% |
34,357,036
+493,954
| +1% | +$36.7M |
|
86
Teledyne Technologies
TDY
$31.8B
| $2.6B | 0.23% |
5,952,763
-87,883
| -1% | -$38.2M |
|
87
Pfizer
PFE
$150B
| $2.55B | 0.23% |
43,258,716
+4,065,502
| +10% | +$201M |
|
88
Sempra
SRE
$56.2B
| $2.54B | 0.23% |
38,471,468
-19,233,204
| -33% | -$1.22B |
|
89
Comcast
CMCSA
$90.4B
| $2.53B | 0.23% |
50,320,863
-2,287,895
| -4% | -$119M |
|
90
Accenture
ACN
$110B
| $2.52B | 0.23% |
6,086,428
+1,721,526
| +39% | +$627M |
|
91
Coca-Cola
KO
$373B
| $2.52B | 0.23% |
42,524,787
+7,979,000
| +23% | +$444M |
|
92
Johnson & Johnson
JNJ
$629B
| $2.48B | 0.22% |
14,494,371
-683,126
| -5% | -$112M |
|
|
93
Morgan Stanley
MS
$342B
| $2.47B | 0.22% |
25,206,452
-28,337,173
| -53% | -$2.82B |
|
94
Burlington
BURL
$22.3B
| $2.46B | 0.22% |
8,439,542
-41,704
| -0.5% | -$11.7M |
|
|
DAY
95
DELISTED
Dayforce
DAY
| $2.45B | 0.22% |
23,413,019
+478,973
| +2% | +$54.9M |
|
96
Okta
OKTA
$25.6B
| $2.44B | 0.22% |
10,889,976
+908,685
| +9% | +$216M |
|
97
Applied Materials
AMAT
$435B
| $2.43B | 0.22% |
15,471,214
-5,619,999
| -27% | -$814M |
|
98
Ball Corp
BALL
$16.4B
| $2.4B | 0.22% |
24,957,171
-475,423
| -2% | -$44M |
|
99
Amphenol
APH
$210B
| $2.39B | 0.22% |
54,756,282
+4,677,336
| +9% | +$189M |
|
100
Ameren
AEE
$30.1B
| $2.39B | 0.22% |
26,888,367
-2,960,812
| -10% | -$252M |
|
Similar funds
T. Rowe Price Associates's Q4 2021 Portfolio in Review
As of Q4 2021, T. Rowe Price Associates held 3,121 positions worth $1.11T, up 4.6% from $1.06T the previous quarter. Its ten largest holdings account for 28% of the portfolio.
T. Rowe Price Associates's Q4 2021 filing shows 186 new, 817 increased, 1,825 reduced and 148 closed positions. Its largest new stake was Rivian: 162,080,423 shares worth $16.1B. The largest sale was Visa, an estimated $4.26B.
By sector, the portfolio is most concentrated in Technology at 27% of assets, up from 25% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- T. Rowe Price Associates's largest Q4 2021 buy was Rivian: 162,080,423 shares worth $16.1B.
- T. Rowe Price Associates added most to Apple in Q4 2021, an estimated $5.48B increase.
- T. Rowe Price Associates's biggest Q4 2021 reduction was Visa, cutting an estimated $4.26B.
- T. Rowe Price Associates fully exited Acceleron Pharma in Q4 2021, selling an estimated $923M.
- T. Rowe Price Associates's ten largest holdings make up 28% of its $1.11T portfolio in Q4 2021.
- T. Rowe Price Associates opened 186 new positions and closed 148 in Q4 2021.
- T. Rowe Price Associates's portfolio value rose 4.6% quarter-over-quarter to $1.11T.
Based on T. Rowe Price Associates's 13F filing for Q4 2021, filed 14 Feb 2022.